Peter Fecci, MD PhD, is currently an Associate Professor of Neurosurgery, Pathology, and Immunology at Duke University, where he also serves as the Director for the Duke Center for Brain and Spine Metastasis, as well as for the Brain Tumor Immunotherapy Program. A neurosurgeon-scientist, Peter earned his MD PhD at Duke University in 2007, before pursuing his neurosurgical training at Harvard’s Massachusetts General Hospital. While in Boston, he continued his post-doctoral research training at the Dana Farber Cancer Institute. Peter returned to Duke in 2014 to join the neurosurgical faculty, where he focuses clinically on intrinsic brain tumors, both primary and metastatic. He was a recipient of the Sontag Distinguished Scientist Award in 2015 and heads an R01- and Brain SPORE-funded laboratory that focuses on integrating strategies for reversing cancer-induced T cell dysfunction with current immune-based platforms. His recent work on GBM-induced T cell sequestration and exhaustion has produced high profile publications in such journals as Nature Medicine and Clinical Cancer Research. He is actively engaged in exploring novel drug targets that his group has uncovered for side-stepping glioma-imposed immune dysfunction and for newly licensing immune-based approaches in this patient population.